Brief: Ngm Biopharmaceuticals - Planned Initiation Of Phase 1 Studies For Oncology Candidates Ngm707 And Ngm438 Expected In Mid-2021 And Q4 2021 Respectively
12/01/2021 21:18
Jan 12 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIOPHARMACEUTICALS - PLANNED INITIATION OF PHASE 1
STUDIES
FOR ONCOLOGY CANDIDATES NGM707 AND NGM438 EXPECTED IN MID-2021
AND Q4 2021 RESPECTIVELY
* NGM BIOPHARMACEUTICALS INC - TOPLINE DATA READOUT FOR
PHASE 2B
ALPINE 2/3 STUDY OF ALDAFERMIN IN PATIENTS WITH NASH EXPECTED IN
Q2 2021
* NGM BIOPHARMACEUTICALS INC - DATA READOUT FOR
DOSE-FINDING
PORTION OF PHASE 1A/1B STUDY OF NGM120 EXPECTED IN SECOND HALF
OF 2021
Source text for Eikon: ID:nGNX6RygrQ
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors